Search
What are you looking for?
Start main content

State Key Lab & Research Institutes

State Key Lab & Research Institutes

https://www.med.cuhk.edu.hk/research/research-infrastructure/state-key-lab-and-research-institutes/state-key-laboratory-of-translational-oncology
https://www.med.cuhk.edu.hk/research/research-infrastructure/state-key-lab-and-research-institutes/state-key-laboratory-of-translational-oncology

State Key Laboratory of Translational Oncology

(The Chinese University of Hong Kong)

 

Located at the Sir YK Pao Centre for Cancer of the Prince of Wales Hospital, the State Key Laboratory of Translational Oncology (The Chinese University of Hong Kong) is built on several solid foundations. One is CUHK's long-established partnership in cancer research with Sun Yat-sen University, backed by a strong clinical base and the support of the Hospital Authority and the former Food and Health Bureau of the Hong Kong SAR Government. With its strong connections to the Mainland, the State Key Lab (SKL) is in a good position to extend its scientific achievements to the wider Chinese community, spearhead international collaboration in medical research and promote scientific development.

Another foundation is the long tradition of cancer research and care in the local community. CUHK's Hong Kong Cancer Institute was established in 1990 to focus on activities related to cancer and its associated problems.
.

Its Comprehensive Cancer Trials Unit was the first in Hong Kong to be approved by the National Cancer Institute (NCI) in the US for conducting new NCI drug clinical studies. The SKL also collaborates with over 20 top cancer trial centres, including MD Anderson, Mayo Clinic, Johns Hopkins University, Oxford University, Fudan University and Peking University.

The investigators of the SKL are a multidisciplinary group of clinical and basic cancer researchers within CUHK and Sun Yat-sen University. They have conducted intensive research investigating the molecular genetics, signalling pathways, clinical diagnostics and novel therapeutic developments of cancers common to our region, in particular nasopharyngeal cancer, liver cancer and gastric cancer.